Good stuff!
It's only a Phase 1 study, so dosing and safety will be the key focus. In itself, that's not likely to have a significant impact, as efficacy is the big brass ring. That will come later.
A fairly quick trial process, only 26 weeks from start to finish for the patient group. I shouldn't think it will be difficult to recruit Melanoma patients in Qld. Should see trial endpoint result by 4th Qtr 2016.
Ann: Prima unveils Phase I combination study of IMP321, page-4
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
0.020(7.41%) |
Mkt cap ! $421.8M | |||
| Open | High | Low | Value | Volume |
| 27.5¢ | 29.5¢ | 27.0¢ | $1.138M | 3.985M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 63444 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 65000 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |